Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as $2.2 billion. Parabilis is focused on ...
Mathai Mammen, Parabilis Medicines CEO May 18, 2026 11:33 AM EDT DealsR&D After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets Lei Lei Wu News Reporter As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that